Inspire Medical Systems, Inc. (NYSE:INSP) Receives Average Recommendation of "Hold" from Analysts

Key Points

• Inspire Medical Systems has a consensus analyst rating of "Hold" from 21 covering analysts. The breakdown includes 2 sells, 14 holds, 4 buys, and 1 strong buy, with an average 12-month price target of about $81.26.
• Several firms recently adjusted their views and targets: JPMorgan cut its price objective to $54, Truist raised its target to $54, and Bank of America downgraded the stock to underperform with a $39 target.
• The company’s latest quarter beat expectations, posting $0.10 EPS versus an expected loss, and $204.58 million in revenue. Management also set FY2026 guidance at $0.75 to $1.25 EPS.

Inspire Medical Systems, Inc. (NYSE:INSP - Get Free Report) has been given a consensus rating of "Hold" by the twenty-one analysts that are presently covering the firm, MarketBeat.com reports. Two equities research analysts have rated the stock with a sell recommendation, fourteen have given a hold recommendation, four have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $81.2632.

A number of research firms have weighed in on INSP. JPMorgan Chase & Co. cut their price objective on shares of Inspire Medical Systems from $67.00 to $54.00 and set a "neutral" rating on the stock in a research report on Tuesday, May 5th. Truist Financial upped their price target on shares of Inspire Medical Systems from $50.00 to $54.00 and gave the company a "hold" rating in a report on Thursday. Bank of America lowered shares of Inspire Medical Systems from a "neutral" rating to an "underperform" rating and set a $39.00 price objective on the stock. in a research report on Friday, May 22nd. Oppenheimer restated a "market perform" rating on shares of Inspire Medical Systems in a research report on Monday, June 15th. Finally, Zacks Research upgraded Inspire Medical Systems from a "strong sell" rating to a "hold" rating in a report on Monday, July 6th.

Inspire Medical Systems Price Performance

Shares of NYSE INSP opened at $50.53 on Friday. Inspire Medical Systems has a 1-year low of $38.91 and a 1-year high of $147.03. The business's 50 day moving average is $44.36 and its two-hundred day moving average is $58.80. The stock has a market capitalization of $1.46 billion, a P/E ratio of 11.25, a PEG ratio of 5.22 and a beta of 0.71.

Inspire Medical Systems (NYSE:INSP - Get Free Report) last posted its quarterly earnings data on Monday, May 4th. The company reported $0.10 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.28) by $0.38. The business had revenue of $204.58 million during the quarter, compared to analyst estimates of $200.04 million. Inspire Medical Systems had a return on equity of 10.35% and a net margin of 14.33%.The company's revenue for the quarter was up 1.6% on a year-over-year basis. During the same period last year, the company earned $0.10 EPS. Inspire Medical Systems has set its FY 2026 guidance at 0.750-1.250 EPS. As a group, equities research analysts anticipate that Inspire Medical Systems will post 0.93 earnings per share for the current fiscal year.

Institutional Trading of Inspire Medical Systems

Large investors have recently made changes to their positions in the stock. Rheos Capital Works Inc. increased its holdings in shares of Inspire Medical Systems by 124.0% in the 4th quarter. Rheos Capital Works Inc. now owns 117,400 shares of the company's stock valued at $10,828,000 after acquiring an additional 65,000 shares during the period. SG Americas Securities LLC lifted its stake in shares of Inspire Medical Systems by 395.9% during the 4th quarter. SG Americas Securities LLC now owns 38,449 shares of the company's stock worth $3,546,000 after purchasing an additional 30,695 shares during the last quarter. Banque Pictet & Cie SA boosted its position in Inspire Medical Systems by 797.5% during the fourth quarter. Banque Pictet & Cie SA now owns 24,474 shares of the company's stock valued at $2,257,000 after purchasing an additional 21,747 shares in the last quarter. Aberdeen Group plc boosted its position in Inspire Medical Systems by 16.3% during the fourth quarter. Aberdeen Group plc now owns 460,901 shares of the company's stock valued at $42,509,000 after purchasing an additional 64,561 shares in the last quarter. Finally, Assenagon Asset Management S.A. bought a new stake in Inspire Medical Systems during the fourth quarter valued at about $24,441,000. 94.91% of the stock is owned by hedge funds and other institutional investors.

Inspire Medical Systems Company Profile

Inspire Medical Systems, Inc is a medical technology company specializing in implantable neurostimulation devices for the treatment of obstructive sleep apnea (OSA). The company's flagship offering, the Inspire® system, delivers targeted stimulation of the hypoglossal nerve to maintain airway patency during sleep, providing an alternative therapy for patients who are intolerant of or inadequately managed by continuous positive airway pressure (CPAP) devices.

The Inspire system comprises an implantable pulse generator, a sensing lead that monitors breathing patterns, and a stimulation lead that activates the hypoglossal nerve.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.